Platelet Derived Growth Factor Receptor- Alpha D842v Mutation in a Spindle Cell Type Gastrointestinal Stromal Tumor: A Case Report
Main Article Content
Abstract
Molecular genotyping of gastrointestinal stromal tumors is not yet available in the Philippines. We report a case of a 75-year old male with a gastric submucosal mass, who underwent gastroscopic/laparoscopic wedge resection. Histopathology and subsequent immunohistochemical staining with CD117 (CKIT) and DOG1 revealed diagnosis of gastrointestinal stromal tumor, spindle cell variant. On genotyping, the tumor harbored PDGFRA D842V mutation, a subtype resistant to Imatinib treatment.
Downloads
Download data is not yet available.
Article Details
How to Cite
Arceño, J. A., Chua, K., Cabral, L. K., Dumasis, A. J. G., Andal, J. J., Lo, R., Pua, G. L., & Ang, D. (2018). Platelet Derived Growth Factor Receptor- Alpha D842v Mutation in a Spindle Cell Type Gastrointestinal Stromal Tumor: A Case Report. Philippine Journal of Pathology, 3(1), 16. Retrieved from https://philippinejournalofpathology.org/index.php/PJP/article/view/87
Section
Case Reports

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The Philippine Journal of Pathology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on works made open access at http://philippinejournalofpathology.org
References
1. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Path Lab Med. 2006;130(10)1466-78. PMID: 17090188.
2. Pogorzelski M, Falkenhorst J, Bauer S. Molecular subtypes of gastrointestinal stromal tumor requiring specific treatments. Curr Opin Oncol. 2016;28(4):331-7. PMID: 27163723. https://doi.org/10.1097/CCO.0000000000000303.
3. Xu Z, Huo X, Tang C, et al. Frequent KIT mutations in human gastrointestinal stromal tumors. Sci Rep. 2014;4:5907. PMID: 25080996. PMCID: PMC4118194.https://doi.org/10.1038/srep05907.
4. Comandone A, Boglione A. The importance of mutational status in prognosis and therapy of GIST. Recenti Prog Med. 2015;106(1):17-22. PMID: 25621775. https://doi.org/10.1701/1740.18950.
5. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21(23):4342-9. PMID: 14645423. https://doi.org/10.1200/JCO.2003.04.190.
6. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumor: the incidence, prevalence, clinical course and prognostication in the preimatinib mesylate ear – a population-based study in western Sweden. Cancer. 2005;103(4):821-9. PMID: 15648083. https://doi.org/10.1002/cncr.20862.
7. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008;53(3):245–66. PMID: 18312355. https://doi.org/10.1111/j.1365-2559.2008.02977.x.
8. Emile JF, Brahimi S, Coindre JM, et al. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol. 2012;29(3):1765–72. PMID: 21953054. https://doi.org/10.1007/s12032-011-0074-y.
9. Cassier PA, Ducimetière F, Lurkin A, et al. A prospective epidemiological study of new incident GISTs during two consecutive years in Rhone Alpes region: incidence and molecular distribution of GIST in a European region. Br J Cancer. 2010; 103(2):165–70. PMCID: PMC2906738. https://doi.org/10.1038/sj.bjc.6605743.
10. Liang YM, Li XH, Lü YY, Lü YL, Zhong M, Pu XL, Li WM. Prognostic significance of clinicopathologic parameters in gastrointestinal stromal tumor: a study of 156 cases. Zhonghua Bing Li Xue Za Zhi. 2007;36(4):233-8. PMID: 17706113.
11. Tan CB, Zhi W, Shahzad G, Mustacchia P. Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment and future directions. ISRN Gastroenterol. 2012 2012: 595968. PMID: 22577569. PMCID: PMC3332214. https://doi.org/10.5402/2012/595968.
12. Corless CL, Shroeder A, Griffith D, et al. PDGFRA mutations in GISTs: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23(23):5357-64. PMID: 15928335. https://doi.org/10.1200/JCO.2005.14.068.
13. Yoo C, Ryu M, et al. Efficacy of imatinib in patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors. Cancer Res Treat. 2016;48(2):546-52. PMCID: PMC4843750. https://doi.org/10.4143/crt.2015.015.
2. Pogorzelski M, Falkenhorst J, Bauer S. Molecular subtypes of gastrointestinal stromal tumor requiring specific treatments. Curr Opin Oncol. 2016;28(4):331-7. PMID: 27163723. https://doi.org/10.1097/CCO.0000000000000303.
3. Xu Z, Huo X, Tang C, et al. Frequent KIT mutations in human gastrointestinal stromal tumors. Sci Rep. 2014;4:5907. PMID: 25080996. PMCID: PMC4118194.https://doi.org/10.1038/srep05907.
4. Comandone A, Boglione A. The importance of mutational status in prognosis and therapy of GIST. Recenti Prog Med. 2015;106(1):17-22. PMID: 25621775. https://doi.org/10.1701/1740.18950.
5. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21(23):4342-9. PMID: 14645423. https://doi.org/10.1200/JCO.2003.04.190.
6. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumor: the incidence, prevalence, clinical course and prognostication in the preimatinib mesylate ear – a population-based study in western Sweden. Cancer. 2005;103(4):821-9. PMID: 15648083. https://doi.org/10.1002/cncr.20862.
7. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008;53(3):245–66. PMID: 18312355. https://doi.org/10.1111/j.1365-2559.2008.02977.x.
8. Emile JF, Brahimi S, Coindre JM, et al. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol. 2012;29(3):1765–72. PMID: 21953054. https://doi.org/10.1007/s12032-011-0074-y.
9. Cassier PA, Ducimetière F, Lurkin A, et al. A prospective epidemiological study of new incident GISTs during two consecutive years in Rhone Alpes region: incidence and molecular distribution of GIST in a European region. Br J Cancer. 2010; 103(2):165–70. PMCID: PMC2906738. https://doi.org/10.1038/sj.bjc.6605743.
10. Liang YM, Li XH, Lü YY, Lü YL, Zhong M, Pu XL, Li WM. Prognostic significance of clinicopathologic parameters in gastrointestinal stromal tumor: a study of 156 cases. Zhonghua Bing Li Xue Za Zhi. 2007;36(4):233-8. PMID: 17706113.
11. Tan CB, Zhi W, Shahzad G, Mustacchia P. Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment and future directions. ISRN Gastroenterol. 2012 2012: 595968. PMID: 22577569. PMCID: PMC3332214. https://doi.org/10.5402/2012/595968.
12. Corless CL, Shroeder A, Griffith D, et al. PDGFRA mutations in GISTs: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23(23):5357-64. PMID: 15928335. https://doi.org/10.1200/JCO.2005.14.068.
13. Yoo C, Ryu M, et al. Efficacy of imatinib in patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors. Cancer Res Treat. 2016;48(2):546-52. PMCID: PMC4843750. https://doi.org/10.4143/crt.2015.015.